Ekso Bionics Company Leadership
EKSO Stock | USD 0.62 0.02 2.97% |
Ekso Bionics' insiders are aggressively selling. The analysis of insiders' sentiment of trading Ekso Bionics Holdings stock suggests that virtually all insiders are panicking at this time. Ekso Bionics employs about 70 people. The company is managed by 10 executives with a total tenure of roughly 7 years, averaging almost 0.0 years of service per executive, having 7.0 employees per reported executive.
Steven Sherman Chairman Chairman of the Board |
Ekso Bionics' Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
2023-08-17 | Jerome Wong | Disposed 12784 @ 1 | View | ||
2023-05-24 | Steven Sherman | Disposed 45660 @ 1.44 | View | ||
2023-05-08 | Jason C Jones | Disposed 3435 @ 1.57 | View | ||
2022-12-04 | Steven Sherman | Disposed 10576 @ 1.28 | View | ||
2022-11-16 | Jerome Wong | Disposed 723 @ 1.28 | View | ||
2022-10-24 | Steven Sherman | Disposed 5921 @ 1.29 | View | ||
2022-09-22 | Steven Sherman | Disposed 6043 @ 1.75 | View | ||
2022-08-22 | Steven Sherman | Disposed 5572 @ 2.2 | View | ||
2022-08-03 | Jerome Wong | Disposed 1675 @ 1.8 | View | ||
2022-07-25 | Steven Sherman | Disposed 5662 @ 1.75 | View | ||
2022-07-18 | Jerome Wong | Disposed 98 @ 1.71 | View | ||
2022-06-30 | Scott G Davis | Disposed 4997 @ 1.72 | View | ||
2022-06-22 | Steven Sherman | Disposed 5330 @ 1.74 | View | ||
2022-06-15 | Steven Sherman | Disposed 6911 @ 1.9 | View | ||
2022-05-24 | Steven Sherman | Disposed 6597 @ 1.76 | View | ||
2022-04-28 | Steven Sherman | Disposed 6862 @ 2.41 | View | ||
2022-04-20 | Scott G Davis | Disposed 4043 @ 2.62 | View | ||
2022-03-24 | Steven Sherman | Disposed 6389 @ 2.94 | View |
Monitoring Ekso Bionics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Ekso |
Ekso Bionics Management Team Effectiveness
The company has return on total asset (ROA) of (0.2417) % which means that it has lost $0.2417 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7389) %, meaning that it created substantial loss on money invested by shareholders. Ekso Bionics' management efficiency ratios could be used to measure how well Ekso Bionics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 23rd of January 2025, Return On Tangible Assets is likely to drop to -0.61. In addition to that, Return On Capital Employed is likely to drop to -0.69. At this time, Ekso Bionics' Non Currrent Assets Other are very stable compared to the past year. As of the 23rd of January 2025, Intangible Assets is likely to grow to about 5.9 M, while Total Assets are likely to drop about 26 M.As of the 23rd of January 2025, Common Stock Shares Outstanding is likely to grow to about 16.7 M, while Net Loss is likely to drop (11.8 M).
Ekso Bionics Workforce Comparison
Ekso Bionics Holdings is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 27,193. Ekso Bionics adds roughly 70.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Ekso Bionics Profit Margins
The company has Profit Margin (PM) of (0.63) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.64) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.64.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.28 | 0.45 |
|
|
Ekso Bionics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ekso Bionics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ekso Bionics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Ekso Bionics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Steven Sherman over a week ago Disposition of 15599 shares by Steven Sherman of Ekso Bionics subject to Rule 16b-3 | ||
Glenn John over a month ago Disposition of 3462 shares by Glenn John of Ekso Bionics at 2.8197 subject to Rule 16b-3 | ||
Steven Sherman over two months ago Acquisition by Steven Sherman of 242679 shares of Ekso Bionics subject to Rule 16b-3 | ||
Jerome Wong over three months ago Disposition of 12784 shares by Jerome Wong of Ekso Bionics at 0.9956 subject to Rule 16b-3 | ||
Scher Deborah Lafer over six months ago Insider Trading | ||
Jerome Wong over six months ago Disposition of 12784 shares by Jerome Wong of Ekso Bionics at 0.9956 subject to Rule 16b-3 | ||
Jason Jones over six months ago Acquisition by Jason Jones of 12270 shares of Ekso Bionics subject to Rule 16b-3 | ||
Jerome Wong over a year ago Sale by Jerome Wong of 12784 shares of Ekso Bionics |
Ekso Bionics Notable Stakeholders
An Ekso Bionics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Ekso Bionics often face trade-offs trying to please all of them. Ekso Bionics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Ekso Bionics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Steven Sherman | Chairman of the Board | Profile | |
Foon Chwee | President APAC | Profile | |
Ann Cookson | Human Director | Profile | |
Stephan Aderhold | Senior EMEA | Profile | |
Rachael Anderson | Global Growth | Profile | |
Scott Davis | Chief Officer | Profile | |
Katherine Strausser | Principal Engineer | Profile | |
Jason Jones | Chief Officer | Profile | |
Jerome Wong | Corporate Controller | Profile | |
Anthony Pratt | Vice Sales | Profile |
About Ekso Bionics Management Performance
The success or failure of an entity such as Ekso Bionics Holdings often depends on how effective the management is. Ekso Bionics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Ekso management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Ekso management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.58) | (0.61) | |
Return On Capital Employed | (0.65) | (0.69) | |
Return On Assets | (0.47) | (0.50) | |
Return On Equity | (1.09) | (1.14) |
Ekso Bionics Workforce Analysis
Traditionally, organizations such as Ekso Bionics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Ekso Bionics within its industry.Ekso Bionics Manpower Efficiency
Return on Ekso Bionics Manpower
Revenue Per Employee | 261.1K | |
Revenue Per Executive | 1.8M | |
Net Loss Per Employee | 217.1K | |
Net Loss Per Executive | 1.5M | |
Working Capital Per Employee | 172.7K | |
Working Capital Per Executive | 1.2M |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Ekso Bionics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ekso Bionics. If investors know Ekso will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ekso Bionics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.64) | Revenue Per Share | Quarterly Revenue Growth (0.10) | Return On Assets | Return On Equity |
The market value of Ekso Bionics Holdings is measured differently than its book value, which is the value of Ekso that is recorded on the company's balance sheet. Investors also form their own opinion of Ekso Bionics' value that differs from its market value or its book value, called intrinsic value, which is Ekso Bionics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ekso Bionics' market value can be influenced by many factors that don't directly affect Ekso Bionics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ekso Bionics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ekso Bionics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ekso Bionics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.